Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections

Patients with chronic urinary and urogenital multidrug resistant bacterial infections received phage therapy (PT) using intravesical or intravesical and intravaginal phage administration. A single course of PT did not induce significant serum antibody responses against administered phage. Whilst the...

Descripción completa

Detalles Bibliográficos
Autores principales: Letkiewicz, Sławomir, Łusiak-Szelachowska, Marzanna, Międzybrodzki, Ryszard, Żaczek, Maciej, Weber-Dąbrowska, Beata, Górski, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225094/
https://www.ncbi.nlm.nih.gov/pubmed/34070276
http://dx.doi.org/10.3390/antibiotics10060627
_version_ 1783712021640904704
author Letkiewicz, Sławomir
Łusiak-Szelachowska, Marzanna
Międzybrodzki, Ryszard
Żaczek, Maciej
Weber-Dąbrowska, Beata
Górski, Andrzej
author_facet Letkiewicz, Sławomir
Łusiak-Szelachowska, Marzanna
Międzybrodzki, Ryszard
Żaczek, Maciej
Weber-Dąbrowska, Beata
Górski, Andrzej
author_sort Letkiewicz, Sławomir
collection PubMed
description Patients with chronic urinary and urogenital multidrug resistant bacterial infections received phage therapy (PT) using intravesical or intravesical and intravaginal phage administration. A single course of PT did not induce significant serum antibody responses against administered phage. Whilst the second cycle of PT caused a significant increase in antibody levels, they nevertheless remained quite low. These data combined with good therapy results achieved in some patients suggest that this mode of PT may be an efficient means of therapy for urogenital infections and a reliable model for a clinical trial of PT.
format Online
Article
Text
id pubmed-8225094
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82250942021-06-25 Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections Letkiewicz, Sławomir Łusiak-Szelachowska, Marzanna Międzybrodzki, Ryszard Żaczek, Maciej Weber-Dąbrowska, Beata Górski, Andrzej Antibiotics (Basel) Communication Patients with chronic urinary and urogenital multidrug resistant bacterial infections received phage therapy (PT) using intravesical or intravesical and intravaginal phage administration. A single course of PT did not induce significant serum antibody responses against administered phage. Whilst the second cycle of PT caused a significant increase in antibody levels, they nevertheless remained quite low. These data combined with good therapy results achieved in some patients suggest that this mode of PT may be an efficient means of therapy for urogenital infections and a reliable model for a clinical trial of PT. MDPI 2021-05-25 /pmc/articles/PMC8225094/ /pubmed/34070276 http://dx.doi.org/10.3390/antibiotics10060627 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Letkiewicz, Sławomir
Łusiak-Szelachowska, Marzanna
Międzybrodzki, Ryszard
Żaczek, Maciej
Weber-Dąbrowska, Beata
Górski, Andrzej
Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections
title Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections
title_full Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections
title_fullStr Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections
title_full_unstemmed Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections
title_short Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections
title_sort low immunogenicity of intravesical phage therapy for urogenitary tract infections
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225094/
https://www.ncbi.nlm.nih.gov/pubmed/34070276
http://dx.doi.org/10.3390/antibiotics10060627
work_keys_str_mv AT letkiewiczsławomir lowimmunogenicityofintravesicalphagetherapyforurogenitarytractinfections
AT łusiakszelachowskamarzanna lowimmunogenicityofintravesicalphagetherapyforurogenitarytractinfections
AT miedzybrodzkiryszard lowimmunogenicityofintravesicalphagetherapyforurogenitarytractinfections
AT zaczekmaciej lowimmunogenicityofintravesicalphagetherapyforurogenitarytractinfections
AT weberdabrowskabeata lowimmunogenicityofintravesicalphagetherapyforurogenitarytractinfections
AT gorskiandrzej lowimmunogenicityofintravesicalphagetherapyforurogenitarytractinfections

Ejemplares similares